ARTICLE | Clinical News

PRCA rates declining

September 30, 2004 7:00 AM UTC

Researchers published that the worldwide incidence of epoetin-associated, antibody-mediated pure red-cell aplasia (PRCA) has decreased because of procedures that were adopted to ensure appropriate storage, handling and administration of Eprex epoetin alfa from Johnson & Johnson (JNJ). Eprex is marketed for patients with chronic kidney disease. Since the peak incidence of PRCA associated with all epoetin drugs in 2001, researchers said the worldwide exposure-adjusted incidence has decreased by 83%. ...